Physician profile
John P Schilling
NPI 1902885585
$2,495.49
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,572 · 2020: $115 · 2021: $808.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $2,170.40 | 2019-2021 | |
| Roche Diagnostics Corporation | $55.59 | 2019-2020 | |
| Abbvie INC. | $53.60 | 2019-2020 | |
| Allergan, INC. | $40.74 | 2019-2020 | |
| Therapeuticsmd, INC. | $31.36 | 2019-2021 | |
| Eisai INC. | $23.37 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.54 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $19.44 | 2019 | |
| Boston Scientific Corporation | $18.13 | 2019 | |
| Lupin INC. | $15.88 | 2019 | |
| Galderma Laboratories, L.P. | $15.39 | 2021 | |
| Novo Nordisk INC | $14.57 | 2019 | |
| Duchesnay USA Incorporated | $14.48 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Schilling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.